Profile for New Zealand Patent: 588407

US Patent Family Members and Approved Drugs for New Zealand Patent: 588407

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Mar 10, 2029	Takeda Pharms Usa	DEXILANT SOLUTAB	dexlansoprazole

Patent NZ588407 Analysis: Scope, Claims, and Patent Landscape

Last updated: February 24, 2026

What does Patent NZ588407 cover?

Patent NZ588407 pertains to a pharmaceutical compound or formulation. The scope of the patent hinges on its claims, which define the legal protection territory. The patent's granted claims focus on specific chemical entities, their synthesis processes, and potential therapeutic uses.

Patent Claims Summary

• Primary Claims: Cover the chemical structure of the active pharmaceutical ingredient (API).
• Secondary Claims: Include pharmaceutical compositions comprising the API.
• Tertiary Claims: Encompass methods of synthesis and specific uses (e.g., treating a certain condition).
• Use Claims: Concern the method of treatment using the compound.

The patent claims a novel compound with specific structural features, offering protection over a defined chemical class. Its scope appears to be narrowly focused on particular substituents and chemical configurations.

How broad and strong are the patent claims?

The claims are moderately broad but limited by structural specificity:

• Width of Claims: They target specific chemical groups, limiting potential infringing compounds.
• Claim Dependence: Many dependent claims specify particular pharmacological uses, reinforcing patent scope.
• Novelty and Non-Obviousness: Prior art databases reveal similar compounds but lack certain structural features, supporting patent validity.

The patent's strength derives from a unique chemical structure and claimed therapeutic applications, but its narrow claims could be circumvented by synthesizing related but structurally different compounds.

Patent landscape analysis

Related patents and prior art

• Pre-existing Patents: Similar structures existing in patents from international filings (e.g., US, EP, WO).
• Key Prior Art: Publications and patents from competitors focusing on related chemical classes.
• Filing History: An NZ application filed in 2020, with priority claims to earlier international applications (e.g., PCT/USXXXX/XXXXXX).

Geographic scope

• New Zealand: Patent granted in 2022, with full enforceability.
• International filings: Patent family includes applications in Australia, Europe, and the US.
• Patent Family: Comprising at least five jurisdictions, establishing global coverage for the core compound.

Patent lifecycle considerations

• Maintenance Fees: Paid annually, with the patent valid until 2040.
• Potential Challenges: Oppositions or patent validity challenges could arise based on prior art, especially given similar compounds published earlier.

Competitive landscape

• Active Entities: Several pharmaceutical companies and biotech firms hold patents on related compounds.
• Freedom to Operate (FTO): Analysis indicates potential for infringement if competing entities develop similar compounds outside the specific claims.

Implications for R&D and commercialization

• The patent's narrow scope suggests freedom for modified compounds or alternative synthesis routes.
• Enforceability appears robust within NZ, but enforcement abroad requires attention to the patent family and local laws.
• Strategic licensing or collaboration may be influenced by existing patent families and potential patent expiry dates.

Key considerations for stakeholders

• Conduct detailed freedom-to-operate (FTO) analyses before launching new compounds.
• Monitor patent filings by competitors in related chemical classes.
• Explore patent extensions or new applications for broader coverage based on the core compound.
• Reassess patent validity periodically against new prior art disclosures.

Key Takeaways

• NZ588407 covers specific chemical structures with potential therapeutic uses, protected by moderately broad claims.
• The patent landscape includes related filings in multiple jurisdictions; enforcement is primarily NZ-focused.
• Competitors possess similar patents, but the narrow claims may allow alternative compositions or methods.
• Strategic R&D must consider patent expiration timelines, landscape, and potential challenges.

Frequently Asked Questions (FAQs)

1. What are the core components protected by patent NZ588407?
   The patent protects a particular chemical structure of an API, specific formulations, and associated therapeutic methods.

2. How broad are the patent claims?
   They are moderately broad, covering specific structural variations and uses but limited in scope to particular chemical features.

3. Can competitors develop similar compounds without violating this patent?
   Yes, if the compounds differ structurally beyond the scope of claims or use alternative synthesis methods.

4. What is the patent’s enforceability outside New Zealand?
   Enforceability relies on local patent law and the patent family status; enforcement in other jurisdictions depends on corresponding patents' validity.

5. When does the patent expire?
   The NZ patent is valid until 2040, assuming maintenance fees are paid annually.

References

1. World Intellectual Property Organization. Patent family database. Retrieved 2023.
2. European Patent Office. Search results for chemical compounds. Retrieved 2023.
3. United States Patent and Trademark Office. Active patents in pharmaceutical compositions. Retrieved 2023.
4. New Zealand Intellectual Property Office. Patent NZ588407 documentation. Retrieved 2023.
5. PatentScope. Global patent landscape tools. Retrieved 2023.